Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DSP 3905

Next Previous
Drug Profile

DSP 3905

Alternative Names: ANP-390; DSP-3905

Latest Information Update: 02 Feb 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sunovion Pharmaceuticals
  • Class Analgesics
  • Mechanism of Action Nav1.7 voltage-gated sodium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Neuropathic pain

Most Recent Events

  • 25 Oct 2023 Sumitomo Pharma completes a phase I trial in Neuropathic pain in USA
  • 25 Oct 2023 AlphaNavi Pharma exercises option regarding DSP 3905 under development for Neuropathic pain by Sumitomo Pharma
  • 27 Jul 2023 Phase I development in Neuropathic pain is still ongoing in USA (PO) (Sumitomo Dainippon Pharma's pipeline, July 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top